^
    Back
    Association details:
    Biomarker:NTRK2 fusion
    Cancer:Thyroid Gland Hurthle Cell Carcinoma
    Drug:Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Hurthle cell cancer: Consider systemic therapy…Larotrectinib or entrectinib for patients with NTRK gene fusion-positive advanced solid tumors.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Solid Tumor)
    New
    Title:

    entrectinib (Rozlytrek ®) is accepted for use within NHSScotland

    Excerpt:
    entrectinib (Rozlytrek) is accepted for use within NHSScotland...as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion